Symbols / TEVA
TEVA Chart
About
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders – chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 39.16B |
| Enterprise Value | 52.68B | Income | 1.41B | Sales | 17.26B |
| Book/sh | 6.88 | Cash/sh | 3.09 | Dividend Yield | — |
| Payout | 0.00% | Employees | 31173 | IPO | — |
| P/E | 27.79 | Forward P/E | 10.88 | PEG | — |
| P/S | 2.27 | P/B | 4.89 | P/C | — |
| EV/EBITDA | 10.63 | EV/Sales | 3.05 | Quick Ratio | 0.54 |
| Current Ratio | 1.04 | Debt/Eq | 217.72 | LT Debt/Eq | — |
| EPS (ttm) | 1.21 | EPS next Y | 3.09 | EPS Growth | — |
| Revenue Growth | 11.40% | Earnings | 2026-05-06 | ROA | 6.17% |
| ROE | 20.79% | ROIC | — | Gross Margin | 51.79% |
| Oper. Margin | 27.28% | Profit Margin | 8.17% | Shs Outstand | 1.16B |
| Shs Float | 1.07B | Short Float | 3.32% | Short Ratio | 3.61 |
| Short Interest | — | 52W High | 37.35 | 52W Low | 12.47 |
| Beta | 0.72 | Avg Volume | 9.97M | Volume | 2.53M |
| Target Price | $38.05 | Recom | Buy | Prev Close | $33.92 |
| Price | $33.62 | Change | -0.88% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$38.05
Mean price target
2. Current target
$33.62
Latest analyst target
3. DCF / Fair value
$31.40
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$33.62
Low
$28.00
High
$45.00
Mean
$38.05
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-18 | main | Truist Securities | Buy → Buy | $42 |
| 2026-02-09 | main | Goldman Sachs | Buy → Buy | $45 |
| 2026-01-30 | main | Barclays | Overweight → Overweight | $38 |
| 2026-01-29 | main | Scotiabank | Sector Outperform → Sector Outperform | $40 |
| 2026-01-29 | main | Truist Securities | Buy → Buy | $38 |
| 2026-01-06 | main | Jefferies | Buy → Buy | $40 |
| 2025-12-22 | main | Piper Sandler | Overweight → Overweight | $40 |
| 2025-12-19 | main | Goldman Sachs | Buy → Buy | $35 |
| 2025-12-16 | main | JP Morgan | Overweight → Overweight | $35 |
| 2025-12-09 | main | B of A Securities | Buy → Buy | $32 |
| 2025-12-09 | init | Barclays | — → Overweight | $35 |
| 2025-12-08 | main | Goldman Sachs | Buy → Buy | $31 |
| 2025-12-05 | init | Scotiabank | — → Sector Outperform | $35 |
| 2025-11-06 | main | JP Morgan | Overweight → Overweight | $28 |
| 2025-10-03 | main | JP Morgan | Overweight → Overweight | $26 |
| 2025-09-24 | main | UBS | Buy → Buy | $26 |
| 2025-06-26 | main | UBS | Buy → Buy | $23 |
| 2025-06-06 | init | Goldman Sachs | — → Buy | $24 |
| 2025-05-28 | init | Truist Securities | — → Buy | $25 |
| 2025-05-12 | up | JP Morgan | Neutral → Overweight | $23 |
- Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year? - Yahoo Finance Wed, 25 Feb 2026 14
- Teva Stock: CEO Emphasizes The 'Remarkable Story' Behind Its Guidance - Investor's Business Daily Wed, 28 Jan 2026 08
- Teva Pharmaceutical Industries (TEVA) Stock Analysis: Navigating an 11.18% Potential Upside - DirectorsTalk Interviews Mon, 23 Feb 2026 19
- Truist boosts Teva (TEVA) stock target amid pipeline growth opportunities - MSN Fri, 20 Feb 2026 09
- Teva lines up three March healthcare investor talks - Stock Titan ue, 24 Feb 2026 21
- Has Teva (TEVA) Run Too Far After Its 102% One-Year Share Price Surge? - simplywall.st ue, 24 Feb 2026 11
- Teva Stock Is Jumping. Why Investors Are So Optimistic on the Drugmaker. - Barron's Mon, 12 Jan 2026 08
- Teva Pharmaceuticals and Medincell Announce FDA Acceptance of New Drug Application for Long-Acting Injectable Olanzapine (TEV-'749) for Schizophrenia Treatment - Quiver Quantitative Fri, 20 Feb 2026 19
- Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals - Business Wire hu, 19 Feb 2026 21
- Teva Pharmaceuticals Seeks FDA Greenlight For New Schizophrenia Treatment - Stocktwits Fri, 20 Feb 2026 20
- Teva, Medincell granted FDA review for long-acting antipsychotic - Seeking Alpha Sat, 21 Feb 2026 14
- Monaco Asset Management SAM Has $1.01 Million Stake in Teva Pharmaceutical Industries Ltd. $TEVA - MarketBeat Sat, 21 Feb 2026 12
- Once-a-month schizophrenia shot tested without 3-hour clinic wait - Stock Titan Fri, 20 Feb 2026 19
- Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong Recent Share Price Momentum - Yahoo Finance Mon, 23 Feb 2026 18
- Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Its Strong Recent Share Price Momentum - simplywall.st Mon, 23 Feb 2026 05
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 77400 | 2340646.0 | — | Sale at price 30.24 per share. | MIGNONE ROBERTO A. | Director | — | 2025-12-16 00:00:00 | I |
| 1 | 115468 | 3311126.0 | — | Sale at price 28.68 per share. | DANIELL RICHARD | Officer | — | 2025-12-09 00:00:00 | D |
| 2 | 216892 | 6230754.0 | — | Sale at price 28.70 - 28.75 per share. | SABAG MARK | Officer | — | 2025-12-09 00:00:00 | D |
| 3 | 115468 | 2124542.0 | — | Conversion of Exercise of derivative security at price 16.99 - 18.61 per share. | DANIELL RICHARD | Officer | — | 2025-12-09 00:00:00 | D |
| 4 | 118724 | 2209454.0 | — | Conversion of Exercise of derivative security at price 18.61 per share. | SABAG MARK | Officer | — | 2025-12-09 00:00:00 | D |
| 5 | 30000 | 753321.0 | — | Sale at price 25.11 per share. | FOX CHRISTINE | Officer | — | 2025-11-14 00:00:00 | D |
| 6 | 1113 | 20988.0 | — | Purchase at price 18.86 per share. | MCAVOY DAVID R | Officer | — | 2025-09-05 00:00:00 | D |
| 7 | 52742 | 799437.0 | — | Sale at price 15.16 per share. | HUGHES ERIC A | Officer | — | 2025-08-01 00:00:00 | D |
| 8 | 52742 | nan | — | — | HUGHES ERIC A | Officer | — | 2025-08-01 00:00:00 | D |
| 9 | 55775 | 952464.0 | — | Sale at price 17.08 per share. | KALIF ELIYAHU SHARON | Chief Financial Officer | — | 2025-06-12 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -400.89M | -829.61M | -27.14M | -966.60M |
| TaxRateForCalcs | 0.23 | 0.23 | 0.01 | 0.20 |
| NormalizedEBITDA | 4.88B | 4.38B | 4.27B | 3.91B |
| TotalUnusualItems | -1.74B | -3.61B | -2.71B | -4.83B |
| TotalUnusualItemsExcludingGoodwill | -1.74B | -3.61B | -2.71B | -4.83B |
| NetIncomeFromContinuingOperationNetMinorityInterest | 1.41B | -1.64B | -559.00M | -2.45B |
| ReconciledDepreciation | 1.00B | 1.06B | 1.15B | 1.31B |
| ReconciledCostOfRevenue | 8.32B | 8.48B | 8.20B | 7.95B |
| EBITDA | 3.14B | 777.00M | 1.56B | -925.00M |
| EBIT | 2.14B | -282.00M | 405.00M | -2.23B |
| NetInterestIncome | -985.00M | -1.05B | -1.09B | -991.00M |
| InterestExpense | 916.00M | 1.00B | 1.03B | 930.00M |
| NormalizedIncome | 2.75B | 1.14B | 2.13B | 1.42B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 1.41B | -1.64B | -559.00M | -2.45B |
| TotalExpenses | 13.31B | 13.18B | 12.65B | 12.23B |
| TotalOperatingIncomeAsReported | 2.16B | -303.00M | 433.00M | -2.20B |
| DilutedAverageShares | 1.16B | 1.13B | 1.12B | 1.11B |
| BasicAverageShares | 1.15B | 1.13B | 1.12B | 1.11B |
| DilutedEPS | 1.21 | -1.45 | -0.50 | -2.12 |
| BasicEPS | 1.23 | -1.45 | -0.50 | -2.12 |
| DilutedNIAvailtoComStockholders | 1.41B | -1.64B | -559.00M | -2.45B |
| NetIncomeCommonStockholders | 1.41B | -1.64B | -559.00M | -2.45B |
| NetIncome | 1.41B | -1.64B | -559.00M | -2.45B |
| MinorityInterests | -7.00M | 320.00M | 56.00M | 53.00M |
| NetIncomeIncludingNoncontrollingInterests | 1.42B | -1.96B | -615.00M | -2.50B |
| NetIncomeContinuousOperations | 1.42B | -1.96B | -615.00M | -2.50B |
| EarningsFromEquityInterestNetOfTax | 15.00M | 1.00M | 2.00M | 21.00M |
| TaxProvision | -180.00M | 676.00M | -7.00M | -643.00M |
| PretaxIncome | 1.22B | -1.28B | -624.00M | -3.16B |
| OtherIncomeExpense | -1.74B | -3.60B | -2.72B | -4.86B |
| OtherNonOperatingIncomeExpenses | 1.00M | 10.00M | -9.00M | -26.00M |
| SpecialIncomeCharges | -1.79B | -3.68B | -2.75B | -4.86B |
| GainOnSaleOfPPE | 2.00M | 2.00M | 25.00M | 18.00M |
| GainOnSaleOfBusiness | -22.00M | 15.00M | 3.00M | 46.00M |
| OtherSpecialCharges | 467.00M | 761.00M | 1.04B | 2.07B |
| ImpairmentOfCapitalAssets | 1.03B | 2.56B | 1.08B | 2.45B |
| RestructuringAndMergernAcquisition | 279.00M | 377.00M | 659.00M | 407.00M |
| GainOnSaleOfSecurity | 51.00M | 69.00M | 38.00M | 26.00M |
| NetNonOperatingInterestIncomeExpense | -985.00M | -1.05B | -1.09B | -991.00M |
| TotalOtherFinanceCost | 69.00M | 48.00M | 66.00M | 61.00M |
| InterestExpenseNonOperating | 916.00M | 1.00B | 1.03B | 930.00M |
| OperatingIncome | 3.95B | 3.36B | 3.19B | 2.69B |
| OperatingExpense | 4.99B | 4.70B | 4.45B | 4.28B |
| ResearchAndDevelopment | 1.01B | 998.00M | 953.00M | 838.00M |
| SellingGeneralAndAdministration | 3.97B | 3.70B | 3.50B | 3.44B |
| SellingAndMarketingExpense | 2.69B | 2.54B | 2.34B | 2.27B |
| GeneralAndAdministrativeExpense | 1.29B | 1.16B | 1.16B | 1.18B |
| OtherGandA | 1.29B | 1.16B | 1.16B | 1.18B |
| GrossProfit | 8.94B | 8.06B | 7.64B | 6.97B |
| CostOfRevenue | 8.32B | 8.48B | 8.20B | 7.95B |
| TotalRevenue | 17.26B | 16.54B | 15.85B | 14.93B |
| OperatingRevenue | 16.83B | 15.80B | 15.28B | 14.50B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 106.56M | 107.00M | 106.00M | 106.00M |
| OrdinarySharesNumber | 1.15B | 1.13B | 1.12B | 1.11B |
| ShareIssued | 1.26B | 1.24B | 1.23B | 1.22B |
| NetDebt | 13.25B | 14.48B | 16.61B | 18.41B |
| TotalDebt | 17.09B | 18.08B | 20.15B | 21.56B |
| TangibleBookValue | -11.87B | -14.19B | -15.06B | -16.10B |
| InvestedCapital | 24.72B | 23.16B | 27.34B | 29.02B |
| WorkingCapital | 490.00M | -244.00M | 238.00M | 582.00M |
| NetTangibleAssets | -11.87B | -14.19B | -15.06B | -16.10B |
| CapitalLeaseObligations | 288.00M | 296.00M | 320.00M | 349.00M |
| CommonStockEquity | 7.91B | 5.37B | 7.51B | 7.80B |
| TotalCapitalization | 22.90B | 21.38B | 25.67B | 26.91B |
| TotalEquityGrossMinorityInterest | 7.91B | 5.72B | 8.13B | 8.60B |
| MinorityInterest | 4.00M | 347.00M | 620.00M | 794.00M |
| StockholdersEquity | 7.91B | 5.37B | 7.51B | 7.80B |
| OtherEquityInterest | 1.00M | |||
| GainsLossesNotAffectingRetainedEarnings | -2.39B | -3.15B | -2.70B | -2.84B |
| OtherEquityAdjustments | -2.39B | -3.15B | -2.70B | -2.84B |
| TreasuryStock | 4.13B | 4.13B | 4.13B | 4.13B |
| RetainedEarnings | -13.76B | -15.17B | -13.53B | -12.97B |
| AdditionalPaidInCapital | 28.13B | 27.76B | 27.81B | 27.69B |
| CapitalStock | 58.00M | 58.00M | 57.00M | 57.00M |
| CommonStock | 58.00M | 58.00M | 57.00M | 57.00M |
| TotalLiabilitiesNetMinorityInterest | 32.83B | 33.61B | 35.35B | 35.41B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 19.38B | 20.81B | 23.11B | 23.94B |
| OtherNonCurrentLiabilities | 3.81B | 4.03B | 4.02B | 3.94B |
| TradeandOtherPayablesNonCurrent | 3.85B | 2.58B | ||
| NonCurrentDeferredLiabilities | 296.00M | 483.00M | 606.00M | 548.00M |
| NonCurrentDeferredTaxesLiabilities | 296.00M | 483.00M | 606.00M | 548.00M |
| LongTermDebtAndCapitalLeaseObligation | 15.27B | 16.30B | 18.48B | 19.45B |
| LongTermCapitalLeaseObligation | 288.00M | 296.00M | 320.00M | 349.00M |
| LongTermDebt | 14.99B | 16.00B | 18.16B | 19.10B |
| CurrentLiabilities | 13.46B | 12.80B | 12.25B | 11.47B |
| OtherCurrentLiabilities | 1.54B | 1.72B | 1.06B | 1.01B |
| CurrentDebtAndCapitalLeaseObligation | 1.82B | 1.78B | 1.67B | 2.11B |
| CurrentDebt | 1.82B | 1.78B | 1.67B | 2.11B |
| OtherCurrentBorrowings | 1.82B | 1.78B | 1.67B | 2.11B |
| PensionandOtherPostRetirementBenefitPlansCurrent | 739.00M | 624.00M | 611.00M | 566.00M |
| CurrentProvisions | 4.14B | 3.68B | 3.54B | 3.75B |
| PayablesAndAccruedExpenses | 5.22B | 5.00B | 5.37B | 4.04B |
| CurrentAccruedExpenses | 2.69B | 2.79B | 2.77B | 2.15B |
| Payables | 2.53B | 2.20B | 2.60B | 1.89B |
| AccountsPayable | 2.53B | 2.20B | 2.60B | 1.89B |
| TotalAssets | 40.75B | 39.33B | 43.48B | 44.01B |
| TotalNonCurrentAssets | 26.80B | 26.77B | 30.99B | 31.96B |
| OtherNonCurrentAssets | 405.00M | 462.00M | 470.00M | 441.00M |
| NonCurrentDeferredAssets | 2.19B | 1.80B | 1.81B | 1.46B |
| NonCurrentDeferredTaxesAssets | 2.19B | 1.80B | 1.81B | 1.46B |
| GoodwillAndOtherIntangibleAssets | 19.78B | 19.57B | 22.56B | 23.90B |
| OtherIntangibleAssets | 3.78B | 4.42B | 5.39B | 6.27B |
| Goodwill | 16.00B | 15.15B | 17.18B | 17.63B |
| NetPPE | 4.42B | 4.95B | 6.15B | 6.16B |
| AccumulatedDepreciation | -4.73B | -4.41B | -5.64B | -5.52B |
| GrossPPE | 9.15B | 9.36B | 11.78B | 11.68B |
| ConstructionInProgress | 377.00M | 1.33B | 1.43B | 1.20B |
| OtherProperties | 345.00M | 367.00M | 397.00M | 419.00M |
| MachineryFurnitureEquipment | 5.85B | 5.48B | 7.23B | 7.35B |
| BuildingsAndImprovements | 2.33B | 1.97B | 2.49B | 2.46B |
| LandAndImprovements | 258.00M | 213.00M | 246.00M | 246.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 13.95B | 12.55B | 12.48B | 12.05B |
| OtherCurrentAssets | 538.00M | 409.00M | 505.00M | 549.00M |
| AssetsHeldForSaleCurrent | 1.84B | 1.77B | 70.00M | 10.00M |
| PrepaidAssets | 1.12B | 1.01B | 1.25B | 1.16B |
| Inventory | 3.18B | 3.01B | 4.02B | 3.83B |
| OtherInventories | 1.00M | -1.00M | ||
| FinishedGoods | 1.90B | 1.78B | 2.35B | 1.99B |
| WorkInProcess | 364.00M | 353.00M | 500.00M | 555.00M |
| RawMaterials | 911.00M | 870.00M | 1.18B | 1.29B |
| Receivables | 3.71B | 3.06B | 3.41B | 3.70B |
| AccountsReceivable | 3.71B | 3.06B | 3.41B | 3.70B |
| AllowanceForDoubtfulAccountsReceivable | -81.00M | -78.00M | -95.00M | -91.00M |
| GrossAccountsReceivable | 3.79B | 3.14B | 3.50B | 3.79B |
| CashCashEquivalentsAndShortTermInvestments | 3.56B | 3.30B | 3.23B | 2.80B |
| CashAndCashEquivalents | 3.56B | 3.30B | 3.23B | 2.80B |
| CashEquivalents | 2.68B | 2.00B | 1.70B | 1.22B |
| CashFinancial | 878.00M | 1.29B | 1.52B | 1.58B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 1.15B | 749.00M | 842.00M | 1.04B |
| RepaymentOfDebt | -4.11B | -1.64B | -4.85B | -1.37B |
| IssuanceOfDebt | 2.30B | 0.00 | 3.15B | 0.00 |
| CapitalExpenditure | -501.00M | -498.00M | -526.00M | -548.00M |
| InterestPaidSupplementalData | 950.00M | 1.00B | 1.08B | 948.00M |
| IncomeTaxPaidSupplementalData | 471.00M | 298.00M | 543.00M | 495.00M |
| EndCashPosition | 3.56B | 3.30B | 3.23B | 2.83B |
| BeginningCashPosition | 3.30B | 3.23B | 2.83B | 2.20B |
| EffectOfExchangeRateChanges | 21.00M | -174.00M | -30.00M | -123.00M |
| ChangesInCash | 235.00M | 247.00M | 423.00M | 759.00M |
| FinancingCashFlow | -2.15B | -1.79B | -1.91B | -1.49B |
| CashFlowFromContinuingFinancingActivities | -2.15B | -1.79B | -1.91B | -1.49B |
| NetOtherFinancingCharges | -337.00M | -150.00M | -212.00M | -118.00M |
| NetIssuancePaymentsOfDebt | -1.81B | -1.64B | -1.70B | -1.37B |
| NetShortTermDebtIssuance | 0.00 | 0.00 | 0.00 | 0.00 |
| ShortTermDebtPayments | 0.00 | 0.00 | -700.00M | 0.00 |
| ShortTermDebtIssuance | 0.00 | 0.00 | 700.00M | 0.00 |
| NetLongTermDebtIssuance | -1.81B | -1.64B | -1.70B | -1.37B |
| LongTermDebtPayments | -4.11B | -1.64B | -4.15B | -1.37B |
| LongTermDebtIssuance | 2.30B | 0.00 | 2.45B | 0.00 |
| InvestingCashFlow | 737.00M | 792.00M | 968.00M | 656.00M |
| CashFlowFromContinuingInvestingActivities | 737.00M | 792.00M | 968.00M | 656.00M |
| NetOtherInvestingChanges | 5.00M | 2.00M | -5.00M | 1.00M |
| InterestReceivedCFI | 1.21B | 1.29B | 1.48B | 1.14B |
| NetInvestmentPurchaseAndSale | -15.00M | -31.00M | -46.00M | 3.00M |
| SaleOfInvestment | 42.00M | 40.00M | 0.00 | 4.00M |
| PurchaseOfInvestment | -57.00M | -71.00M | -46.00M | -1.00M |
| NetBusinessPurchaseAndSale | 34.00M | 28.00M | 68.00M | 61.00M |
| SaleOfBusiness | 34.00M | 43.00M | 68.00M | 68.00M |
| PurchaseOfBusiness | 0.00 | -15.00M | 0.00 | -7.00M |
| NetPPEPurchaseAndSale | -501.00M | -498.00M | -526.00M | -548.00M |
| SaleOfPPE | 311.00M | |||
| PurchaseOfPPE | -501.00M | -498.00M | -526.00M | -548.00M |
| OperatingCashFlow | 1.65B | 1.25B | 1.37B | 1.59B |
| CashFlowFromContinuingOperatingActivities | 1.65B | 1.25B | 1.37B | 1.59B |
| ChangeInWorkingCapital | -1.37B | -435.00M | -72.00M | 1.35B |
| ChangeInOtherCurrentAssets | -1.33B | -1.10B | -1.52B | -828.00M |
| ChangeInPayablesAndAccruedExpense | -15.00M | 258.00M | 1.59B | 2.01B |
| ChangeInPayable | -15.00M | 258.00M | 1.59B | 2.01B |
| ChangeInAccountPayable | -15.00M | 258.00M | 1.59B | 2.01B |
| ChangeInInventory | 152.00M | 166.00M | -147.00M | -163.00M |
| ChangeInReceivables | -173.00M | 245.00M | 12.00M | 334.00M |
| ChangesInAccountReceivables | -173.00M | 245.00M | 12.00M | 334.00M |
| OtherNonCashItems | 81.00M | 560.00M | 61.00M | -91.00M |
| StockBasedCompensation | 157.00M | 123.00M | 121.00M | 124.00M |
| AssetImpairmentCharge | 1.03B | 2.56B | 1.08B | 2.45B |
| DeferredTax | -671.00M | -634.00M | -317.00M | -1.06B |
| DeferredIncomeTax | -671.00M | -634.00M | -317.00M | -1.06B |
| DepreciationAmortizationDepletion | 1.00B | 1.06B | 1.15B | 1.31B |
| DepreciationAndAmortization | 1.00B | 1.06B | 1.15B | 1.31B |
| AmortizationCashFlow | 581.00M | 588.00M | 616.00M | 732.00M |
| AmortizationOfIntangibles | 581.00M | 588.00M | 616.00M | 732.00M |
| Depreciation | 421.00M | 471.00M | 537.00M | 576.00M |
| OperatingGainsLosses | -22.00M | -41.00M | 10.00M | 104.00M |
| GainLossOnInvestmentSecurities | -41.00M | 10.00M | 104.00M | |
| GainLossOnSaleOfPPE | 10.00M | 104.00M | ||
| GainLossOnSaleOfBusiness | 0.00 | -22.00M | -41.00M | 10.00M |
| NetIncomeFromContinuingOperations | 1.42B | -1.96B | -615.00M | -2.50B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TEVA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|